The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

If you’ve never stepped foot into one of these detailed action-adventure-infused worlds, you’ve been missing out. Action-adventure games are always hugely popular as they give players the ...

There’s a reason that the most successful genre on the home market has been the same for over a generation now: People love action movies. They allow us to escape reality and enter a world where ...

AbbVie’s two immunology mainstays, Rinvoq and Skyrizi, which often took the top two spending spots throughout 2024, fell to third and fourth, respectively, this time around. With $42.5 million ...

To curate this list, he dives into Max’s catalogue every month to surface exciting, white-knuckle action titles — using his taste and a lifetime of cinema study as his guide, instead of ...

Thankfully, this is where the hybrid action RPG comes in. Combining tenets of both, the ARPG can be seen as a progression of the slower-paced genre. The RPG side still brings character leveling ...

Rinvoq total sales were more than $1.8 billion ... we reinstated our original Alle consumer loyalty program earlier this month. This action has been met with a rapid and favorable response ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets ...